SCYNEXIS, Inc. (SCYX) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

SCYNEXIS, Inc. (SCYX) closed at USD 3.96 on 2026-10-14, a change of -30.8 % over the past year, with a market capitalization of USD 38.9M.

SCYNEXIS, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

SCYNEXIS, Inc. key figures

Previous close

USD 3.96 (2026-10-14)

1-year change

-30.8 %

Market cap

USD 38.9M

Enterprise value

USD -13.24M

P/E ratio (trailing)

-4.44

P/E ratio (forward)

-1.69

EPS (trailing)

-0.88

EPS (forward)

-2.32

PEG ratio

n/a

Price to book

0.58

Revenue growth

-82.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.34

Employees

18

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About SCYNEXIS, Inc.

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for SCYNEXIS, Inc. and compare it with other stocks.